Germany's AiCuris raised close to $75 million in its second venture round, one of the biggest series the country's life sciences industry has seen in recent years. The developer has a pipeline of anti-infectives for herpes simplex virus, HIV, hepatitis B, hepatitis C, and multi-resistant bacteria. And the developer says it is actively seeking out-licensing deals for several of its programs. The company was spun out of Bayer four years ago. AiCuris release | Report